Dataset opportunity
Learnivf — Gelegenheid voor medische beeldvormingsdataset
Matige dataset voor medische beeldvorming, beheerd door Learnivf, bruikbaar voor Diagnostische AI en Computer Vision.
Score
68.6
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Diagnostics market was valued at $7.03 billion in 2025, projected to grow at a CAGR of 46.06% (2026-2034).
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Learnivf beheert een gespecialiseerde Medical Imaging Dataset gericht op in-vitrofertilisatie (IVF), met Image-collecties met hoge resolutie gekoppeld aan bijbehorende medische dossiers. Deze gestructureerde gegevens, ondersteund door regelgevende documentatie, zijn uitermate geschikt voor het trainen en valideren van Diagnostic AI-algoritmen gericht op het verbeteren van resultaten in de reproductieve geneeskunde, een gebied waar hoogwaardige, specifieke gegevens aanzienlijke analytische voordelen bieden.
De wereldwijde markt voor Diagnostic AI werd gewaardeerd op $7,03 miljard in 2025 en zal naar verwachting groeien met een explosieve 46,06% CAGR. [3] Ondanks toegangscomplexiteiten met betrekking tot GDPR, gevoelige PII en klinische governance, bieden de klinische diepgang en zeldzaamheid van deze dataset een unieke kans. Voor AI-ontwikkelaars is het navigeren door deze hindernissen een strategische investering om toegang te krijgen tot een uniek data-actief en te profiteren van deze snelgroeiende markt. ⚠ Zorgvuldigheid (waardevolle gegevens, onderhandelbare toegang): Dataset bevat zeer gevoelige medische informatie (PII en medische dossiers) onderworpen aan strikte GDPR en Italiaanse gezondheidsregelgeving.; Data-eigendom is voornamelijk in handen van de klinische entiteit CFA (Centro Fecondazione Assistita).; Toegang vereist het navigeren door ethische commissies voor klinisch onderzoek en patiënttoestemmingskaders. · corporate: onafhankelijk.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
Dit bewijs toont collectief aan dat de houder een grootschalige, propriëtaire dataset van medische beelden van menselijke vruchtbaarheid bezit, gegenereerd uit meer dan 1200 jaarlijkse IVF-cycli en ondersteund door Europese regelgevende autorisatie. Deze unieke collectie is cruciaal voor medische AI-bedrijven die diagnostische tools ontwikkelen in de snel uitbreidende AI in Diagnostics-markt, die naar verwachting met meer dan 46% per jaar zal groeien. De hoge kwaliteit van de gegevens, aangegeven door het gebruik ervan in geavanceerde klinische training, biedt een aanzienlijk concurrentievoordeel voor het bouwen en valideren van de volgende generatie fertility AI-modellen.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
Buyer demand is exceptionally high, driven by the explosive growth in the Diagnostic AI market, which is projected to expand at a 46.06% CAGR. [3]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=company_owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 data-appetite signals (2 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — This is an ideal target; it is the training academy for Italy's largest IVF clinic, generating unique, proprietary medical and imaging data as a by-product of its core business, which is selling high-value training courses, not data or software. [1, 3, 6] Issues: The data is highly sensitive human medical data (images of gametes/embryos, patient outcomes), which will be subject to stringent GDPR and ethical constraints r; The entity is a combination of a training academy (LearnIVF) and a clinical center (CFA), potentially complicating ownership and rights to the data. [3]
- Deep Qualification90
⚠ needs review — LearnIVF is the training and research brand for the CFA IVF clinic. It holds valuable imaging and clinical data as a byproduct, but ownership resides with the clinical entity (CFA) and is heavily restricted by its medical nature and GDPR. [data is owned by the company's customers]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
This evidence confirms a high-volume clinical source, with over 1200 IVF cycles performed annually, providing the scale of real-world longitudinal data necessary for training robust diagnostic AI.
Image collection
This indicates the existence of a specialized collection of high-quality embryo and oocyte images, curated for advanced clinical training and ideal for developing and validating precision AI models.
Regulatory records
This confirms official European regulatory authorization as a tissue institute, a critical validation that de-risks data acquisition and ensures compliance for buyers in the medical AI sector.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Learnivf Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Diagnostics market was valued at $7.03 billion in 2025, projected to grow at a CAGR of 46.06% (2026-2034) (source: Fortune Business Insights). [3]. Investment score 68.6/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Atriva Therapeutics — Medische Beeldvormings Dataset Mogelijkheid
View opportunity →gezondheidszorgAcandis — Gelegenheid voor medische beeldvormingsdataset
View opportunity →gezondheidszorgSedivention — Medische Beeldvormingsdataset Mogelijkheid
View opportunity →Data Academy
Learn before you deal
- Zijn uw gegevens geld waard?3 min read
- Hoeveel is een dataset waard?3 min read
- Hoe een datatransactie verloopt3 min read
News & Insights
Latest from the briefing
- Hoe gecentraliseerde verwijdering de economie van databrokerage opnieuw vormgeeft
- Verborgen aansprakelijkheden bij het kopen van ongeverifieerde data van brokers
- Hoe Universele Verwijderingsmechanismen de Waardering van Consumentengegevens Beïnvloeden